

TABLE 2. Peak Season Influenza Vaccine Effectiveness Against Outpatient Laboratory-Confirmed Influenza, Active Component, U.S. Armed Forces, 2025–2026^a

Type of Influenza	Cases		Test-Negative Controls		Unadjusted VE		Adjusted VE	
	No.	% Vaccinated	No.	% Vaccinated	%	95% CI	%	95% CI ^b
Overall	7,954	80	21,628	86	34	29, 38	30	25, 35
A, any subtype ^c	6,248	78	21,628	86	42	37, 46	35	29, 40
A(H1N1)pdm09	71	85	21,628	86	11	-70, 53	26	-44, 62
A(H3N2)	819	69	21,628	86	63	57, 68	52	43, 59
B ^c	1,733	88	21,628	86	-15	-33, 1	6	-10, 19

Abbreviations: VE, vaccine effectiveness; No., number; CI, confidence interval.

^aPeak season surveillance period defined as Dec. 1, 2025–Mar. 31, 2026.

^bAdjusted for sex, age category, prior vaccination (any influenza vaccine in previous 5 years), and month of diagnosis.

^cInfluenza type A (any subtype) and B include 27 cases positive for both influenza A and B.